HRB
52
5
CHK
53
5
CCL
36
-4
IBM
50
3
FTI
61
-2
SJM
70
2
ALL
38
3
DHI
52
3
MOS
36
-2
GPS
37
4
MCK
41
7
AXP
48
-4
AEP
59
6
JNJ
42
3
MET
43
-8
HES
62
3
KMI
61
4
GRMN
45
2
LLY
70
2
CRM
54
4
HRB
52
5
CHK
53
5
CCL
36
-4
IBM
50
3
FTI
61
-2
SJM
70
2
ALL
38
3
DHI
52
3
MOS
36
-2
GPS
37
4
MCK
41
7
AXP
48
-4
AEP
59
6
JNJ
42
3
MET
43
-8
HES
62
3
KMI
61
4
GRMN
45
2
LLY
70
2
CRM
54
4
Financhill
Back

Intellia Therapeutics 10K Form

Sell
31

NTLA
Intellia Therapeutics

Last Price:
38.29
Seasonality Move:
10.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NTLA News And Ratings

See the #1 stock for the next 7 days that we like better than NTLA

NTLA Financial Statistics

Sales & Book Value

Annual Sales: $52.12M
Cash Flow: $-93.78M
Price / Cash Flow: 0
Annual Sales: $14.19
Price / Book: 2.73

Profitability

EPS (TTM): -6.18000
Net Income (TTM): $-474.19M
Gross Margin: --
Return on Equity: -48.04%
Return on Assets: -38.17%

Intellia Therapeutics Earnings Forecast

Key Intellia Therapeutics Financial Ratios

  • The Research & Development expenses have been 805.79% of Revenue.
  • The Net Earning history of NTLA is -909.80% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 0 years.

Intellia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: NTLA
CUSIP: 45826J
Website: intelliatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.61
Quick Ratio: 9.45

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NTLA Technical Analysis vs Fundamental Analysis

Sell
31
Intellia Therapeutics (NTLA) is a Sell

Is Intellia Therapeutics a Buy or a Sell?